Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence

Ricardo Soares-dos-Reis, Jessica Li Tsz-Ching, Su Hyun Kim, Anu Jacob, Daniel Whittam, Emeline Berthelot, Friedemann Paul, Ichiro Nakashima, Janis Siew Noi Tye, Jerôme De Seze, Jiraporn Jitprapaikulsan, Kevin Tan, Li Yang, Liene Elsone, Maria Isabel Leite, Maureen A. Mealy, Michael Levy, Moli Fan, Nadja Siebert, Nasrin AsgariPhilippe Cabre, Sasitorn Siritho, Sean J. Pittock, Stephen Cheng Wing-Ho, Thomas Senger, Tianrong Yeo, Yoshiki Takai, Lekha Pandit, Ho Jin Kim, Jacqueline Palace*

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy characterized by aquaporin-4 antibodies, whose prognosis is influenced by onset age, race, environmental exposures and immunosuppression. Distinguishing the contribution of environment from genetics is challenging. We aimed to compare neuromyelitis optica spectrum disorder (NMOSD) patient outcomes according to self-identified racial group and place of residence. Methods: This retrospective analysis of prospectively collected data included non-white anti-aquaporin-4 antibody positive NMOSD patients under follow-up from 15 centers [United Kingdom, France, Germany, Denmark, Martinique, United States of America, Japan, South Korea, Singapore, Thailand, China (including Hong Kong) and India]. Racial groups were designated: African/Caribbean; South Asian; East Asian (including Southeast Asia). Patients from these racial groups residing outside Africa/Caribbean or Asia were compared with those living in the Caribbean or the Asian areas. Kaplan-Meier survival curves and Cox models were generated using time to sustained Expanded Disability Status Scale≥6.0 or death; time to sustained Kurtzke Visual Function Score≥3.0 or a composite endpoint of all three. Results: Among 821 patients, African/Caribbean patients (n = 206) had the shortest time to immunosuppression and higher visual disability at onset. South Asian patients (n = 65) were younger, had lower visual disability at onset and higher mortality rate. East Asians (n = 550) had the lowest relapse rate and lowest accrued motor disability. Survival analysis of African/Caribbean outside Africa/Caribbean vs those in the Caribbean showed a significant difference in the composite endpoint (p = 0.024,log-rank test), not apparently related to treatment differences. No significant differences between native and those residing outside Asia were found for other racial groups. Conclusion: This NMOSD study reports the effects of place of residence on the outcomes in different races. Place of residence may not be a significant driver of disability among Asian patients, while it may influence African/Caribbean patient outcomes. Validating these findings could help distinguish between genetic causes and potentially modifiable environmental factors.

OriginalsprogEngelsk
Artikelnummer103080
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind53
Antal sider8
ISSN2211-0348
DOI
StatusUdgivet - aug. 2021

Bibliografisk note

Funding Information:
No funding sources directly financed this study.

Funding Information:
Dr. Kim reports grants from National Research Foundation of Korea, personal fees from Alexion Pharmaceuticals, Aprilbio, Celltrion, Eisai, HanAll BioPharma, MDimume, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok, and Viela Bio, other from Viela Bio (formerly MedImmune), other from Multiple Sclerosis Journal, other from Journal of Clinical Neurology, outside the submitted work.

Funding Information:
Dr. Palace reports grants, personal fees and other from Alexion Pharmaceuticals Inc, during the conduct of the study; personal fees from Abide Therapeutics, Alexion Pharmaceuticals, ARGENX, Bayer Schering, Biogen Idec, Chugai Pharma, EuroImmun, Genzyme, MedDay, MedImmune, Merck Serono, Novartis, Roche, Teva, UCB, and Viela Bio; grants from Abide Therapeutics, Alexion Pharmaceuticals, Bayer Schering, Biogen Idec, Chugai Pharma, Genzyme, MedImmune, Merck Serono, Novartis, and Teva, grants from Eugène Devic European Network, the Grant for Multiple Sclerosis Innovation, the John Fell Fund, the Medical Research Council, the MS Society, Myaware, the UK National Institute for Health Research, Oxford Health Services Research Committee, and The Guthy-Jackson Charitable Foundation and AMPLO for research studies, outside the submitted work.

Funding Information:
Dr. Yeo reports grants from National Medical Research Council Singapore, non-financial support from Merck, non-financial support from UCB, outside the submitted work.

Funding Information:
Dr. Soares dos Reis reports non-financial support from Bayer, grants and non-financial support from Biogen, non-financial support from Boehringer-Ingelheim, non-financial support from Daiichi-Sankyo, non-financial support from Eisai, non-financial support from Mylan, from Novartis, personal fees and non-financial support from Roche, non-financial support from Sanofi, outside the submitted work.

Publisher Copyright:
© 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence'. Sammen danner de et unikt fingeraftryk.

Citationsformater